Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14024439 | 0.92 | SYK (0.59) | SYKSRCAURKAAURKBIGF1R | |
| SCHEMBL14024435 | 0.87 | NPC1 (0.52) | SYKAURKANPC1RAB9A | |
| SCHEMBL14024653 | 0.87 | SRC (0.46) | SYKSRCFLT3AURKAAURKB | |
| SCHEMBL15888374 | 0.87 | SRC (0.46) | SYKSRCFLT3AURKAAURKB | |
| SCHEMBL14024570 | 0.86 | KDR (0.55) | SYKSRCFLT3IKBKBCHUK | |
| SCHEMBL14024449 | 0.85 | AURKA (0.54) | SYKAURKAAURKBNPC1RAB9A | |
| SCHEMBL4874759 | 0.85 | SYK (0.55) | SYKFLT3AURKAAURKBIKBKB | |
| SCHEMBL4874875 | 0.82 | NPC1 (0.56) | SYKAURKANPC1RAB9A | |
| SCHEMBL14024438 | 0.82 | NPC1 (0.50) | SYKAURKANPC1RAB9A | |
| SCHEMBL14024417 | 0.80 | EGFR (0.53) | SYKSRCIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | claimed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | SYK 2248/4885SRC 4249/4885FLT3 961/4885 |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | TYMS, KDR, FLT4 | SYK 2737/4885SRC 3671/4885FLT3 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.